Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATP synthase membrane subunit g (ATP5MG) is a minor yet essential component of the mitochondrial F0 complex, which forms part of the multi-subunit mitochondrial ATP synthase (Complex V) responsible for synthesizing ATP from ADP and inorganic phosphate during oxidative phosphorylation[1][2][3]. ATP5MG is anchored in the inner mitochondrial membrane as part of the proton channel (F0 domain) and likely participates in stabilization, assembly, or regulation of the ATP synthase complex. Mutations in ATP5MG and its related genes can result in mitochondrial diseases marked by disrupted ATP synthesis and energy deficiency. While not typically a standalone drug target, the broader ATP synthase complex can be inhibited by compounds like oligomycin, which impede proton translocation, block ATP production, and cause cellular metabolic collapse if administered systemically[2][3]. ATP5MG is conserved and structurally critical in both normal mitochondrial bioenergetics and in pathologies involving impaired oxidative phosphorylation.
Drugs like oligomycin inhibit ATP synthase by blocking proton flow through the F0 complex, preventing ATP synthesis[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP synthase membrane subunit g (ATP5MG).